Journal article
Final analysis of the prevention of early menopause study (POEMS)/SWOG intergroup S0230
HCF Moore, JM Unger, KA Phillips, F Boyle, E Hitre, A Moseley, DJ Porter, PA Francis, LJ Goldstein, HL Gomez, CS Vallejos, AH Partridge, SR Dakhil, AA Garcia, JR Gralow, JM Lombard, JF Forbes, S Martino, WE Barlow, CJ Fabian Show all
Journal of the National Cancer Institute | OXFORD UNIV PRESS INC | Published : 2019
DOI: 10.1093/jnci/djy185
Abstract
Premature menopause is a serious long-term side effect of chemotherapy. We evaluated long-term pregnancy and disease-related outcomes for patients in S0230/POEMS, a study in premenopausal women with stage I-IIIA estrogen receptor-negative, progesterone receptor-negative breast cancer to be treated with cyclophosphamide-containing chemotherapy. Women were randomly assigned to standard chemotherapy with or without goserelin, a gonadotropin-releasing hormone agonist, and were stratified by age and chemotherapy regimen. All statistical tests were two-sided. Of 257 patients, 218 were eligible and evaluable (105 in the chemotherapy + goserelin arm and 113 in the chemotherapy arm). More patients in..
View full abstractRelated Projects (1)
Grants
Awarded by National Institutes of Health
Funding Acknowledgements
Research support for this study was provided by The National Cancer Institute of the National Institutes of Health, Breast Cancer Trials Australia and New Zealand (BCT-ANZ), and AstraZeneca. The Prevention of Early Menopause Study (POEMS)/S0230 trial was performed in collaboration by investigators from the SWOG Cancer Research Group, the International Breast Cancer Study Group, the ECOG-ACRIN Cancer Research Group, and the Alliance for Clinical Trials in Oncology. This study was supported by the National Cancer Institute of the National Institutes of Health under grant awards CA189974, CA180888, CA180819, CA180821, CA075362, CA180820, CA189808, CA180830, CA180801, CA189872, CA189822, CA189953, CA189858, CA180858, CA189954, CA189957, CA189972, CA04919, CA46368, CA68183, CA46282, CA46113, CA76447, CA58416, CA12644, and CA11083; and by Breast Cancer Trials Australia and New Zealand (BCT-ANZ).